Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domenico Russo

Showing results (231-240 of 348) with videos related to

Pageof 35
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseasesAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.
Journal of Nephrology|June 26, 2021
Calcifediol supplementation in adults on hemodialysis: a randomized controlled trialLuigi Morrone, Suetonia C Palmer, Valeria M Saglimbene, et al.
Stem Cells Translational Medicine|November 24, 2025
Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML)Silvia Mutti, Alessia Cavalleri, Anna Sicuranza, et al.
Nutrients|September 9, 2022
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2)Enrico Morello, Francesco Arena, Michele Malagola, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|January 10, 2014
What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study resultsFrancesco Locatelli, Piergiorgio Messa, Antonio Bellasi, et al.
Hematological Oncology|June 4, 2014
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilizationGiuseppe Rossi, Cristina Skert, Enrico Morello, et al.
Bone Marrow Transplantation|February 8, 2024
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donorAnnalisa Paviglianiti, Maud Ngoya, Marta Peña, et al.
Frontiers in Cell and Developmental Biology|November 16, 2020
Advances in CMV Management: A Single Center Real-Life ExperienceMichele Malagola, Caterina Pollara, Nicola Polverelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2013
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromesCarla Filì, Michele Malagola, Matilde Y Follo, et al.
Pageof 35

Showing results (231-240 of 348) with videos related to

Sort By:
Pageof 35
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseasesAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.
Journal of Nephrology|June 26, 2021
Calcifediol supplementation in adults on hemodialysis: a randomized controlled trialLuigi Morrone, Suetonia C Palmer, Valeria M Saglimbene, et al.
Stem Cells Translational Medicine|November 24, 2025
Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML)Silvia Mutti, Alessia Cavalleri, Anna Sicuranza, et al.
Nutrients|September 9, 2022
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2)Enrico Morello, Francesco Arena, Michele Malagola, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|January 10, 2014
What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study resultsFrancesco Locatelli, Piergiorgio Messa, Antonio Bellasi, et al.
Hematological Oncology|June 4, 2014
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilizationGiuseppe Rossi, Cristina Skert, Enrico Morello, et al.
Bone Marrow Transplantation|February 8, 2024
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donorAnnalisa Paviglianiti, Maud Ngoya, Marta Peña, et al.
Frontiers in Cell and Developmental Biology|November 16, 2020
Advances in CMV Management: A Single Center Real-Life ExperienceMichele Malagola, Caterina Pollara, Nicola Polverelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2013
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromesCarla Filì, Michele Malagola, Matilde Y Follo, et al.
Pageof 35